Cyient Ltd
CYIENTCyient Ltd is strength at full price. The numbers are improving — and a P/E at the 89th percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 89th percentile of its own range you are paying full price for it.
The price is in a downtrend (85 weeks in) while the P/E sits at the 89th percentile of its own 11-year range. Underneath, the last four quarters read improving — profit −30.6% year on year, and 127% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Cyient Ltd trades at ₹1,059, in a downtrend and 85 weeks into that stage. That is +7.2% against its own 200-day average. It sits at 66% of a 52-week range of ₹785 to ₹1,201. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks.
Today the stock is in a downtrend — week 85 of stage 4, confirmed. At ₹1,059 it trades +7.2% versus its 200-day average and sits at 66% of its 52-week range (₹785–₹1,201).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +162% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Cyient Ltd trades at 28.9× P/E, at the pricey end of its own range (89th percentile). Its long-run median P/E is 19.0×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 28.9× is at the pricey end of its own range (89th percentile), against a long-run median of 19.0× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −30.6% against a −13.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +0.8%/yr price move, ~+0.3%/yr came from earnings growth and ~+0.5 pp from the multiple (roughly flat); over 10y, of the +8.7%/yr price move, ~+2.3%/yr came from earnings growth and ~+6.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 16% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Cyient Ltd was paying for profit growth of about 12.8% a year. Profit itself has compounded 3.8% a year over the past 10 years. Today the market pays 28.9× P/E, the 89th percentile of its own 11-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is far above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Cyient Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −36.9% latest against +1.9% at its 12-quarter best), ROCE slipping at 12.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −1.2% | +6.5% | +12.0% | +8.9% |
| Profit | −28.5% | −3.4% | +4.9% | +3.8% |
| EPS | −30.6% | −6.1% | +3.1% | +2.9% |
| Share price | −13.7% | −16.0% | +0.8% | +8.7% |
4-Factor Sector Score
34.3/100 — rank 6 of 7 in IT - ER&D · 76% evidence confidence
Cyient Ltd scores 34.3 out of 100 against the 7 companies it is compared with in IT - ER&D, ranking 6. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 9.8 + 7.9 + 7.2 + 9.4 = 34.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Cyient Ltd reported ₹2,076 Cr of revenue in the Jun 26 quarter, +21.3% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at 8.9% a year. The last full year, FY26, came in at ₹7,268 Cr. The last four reported quarters add to ₹7,632 Cr.
FY26 revenue came in at ₹7,268 Cr (−1.2% on the year), capping 10 years at 8.9% compound. The latest quarter (Jun 26) printed ₹2,076 Cr, +21.3% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +3.6% growth against the decade's 8.9% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +3.2% over the last 4 quarters against +3.4%/yr over the last 8 — stabilising; TTM profit −36.9% vs −22.0%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Cyient Ltd's operating margin is 13.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0% to 19.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.0%, +0.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0%–19.0%.
🚨 Why the margin moved: operating margin went −0.7 pp year on year while gross margin went −4.6 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Cyient Ltd earned ₹109 Cr of net profit in the Jun 26 quarter, −30.6% year on year. Full-year FY26 profit was ₹463 Cr. The 10-year compound rate is 3.8%. That is 5.3% of the quarter's revenue. The same quarter a year earlier earned ₹157 Cr.
Jun 26 profit was ₹109 Cr, −30.6% year on year. On the full year, FY26 printed ₹463 Cr (−28.5%), and the 10-year compound rate is 3.8%.
🚨 Why profit moved: revenue contributed +21.3% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −35.7% vs revenue +3.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 127% of Cyient Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹787 Cr of operating cash against ₹463 Cr of profit. After ₹359 Cr of capital spending, ₹428 Cr was left as free cash.
FY26: operating cash of ₹787 Cr against reported profit of ₹463 Cr, leaving free cash of ₹428 Cr after ₹359 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 127% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 127%: the cash cycle stretched 252 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Cyient Ltd's cash conversion cycle runs 119 days in FY26, up from −133 days in FY21. Capital spending ran ₹1,032 Cr over the last 3 years. At FY26 sales of ₹7,268 Cr each day of that cycle holds about ₹19.9 Cr, so roughly ₹2,370 Cr sits inside the business at any moment.
FY26: debtors at 66 days, inventory at 303 days — roughly 10.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 119 days, looser than FY21's −133.
The full loop: cash goes out to suppliers and production on day 0; stock waits 303 days to sell; customers pay about 66 days after that; and suppliers themselves are paid at 249 days — netting out to the 119-day cycle.
In money terms: at FY26 sales of ₹7,268 Cr, each day of the cycle holds about ₹19.9 Cr — so the 119-day loop keeps roughly ₹2,370 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,032 Cr over the last 3 fiscal years against ₹812 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹5.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Cyient Ltd earns a ROCE of 12% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 6.4% net margin on 0.88× asset turns.
FY26 ROCE is 12%.
Why the return is what it is — the wiring (FY26): 6.4% net margin × 0.88× asset turns × 1.45× balance-sheet leverage ≈ 8.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 16% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Cyient Ltd carries ₹431 Cr of borrowings against ₹5,682 Cr of equity in FY26, a debt-to-equity of 0.08. Operating profit covers the interest bill 15×. Over 5 years borrowings went from ₹577 Cr to ₹431 Cr. Capital spending ran ₹1,032 Cr across the last 3 of those years.
FY26: borrowings of ₹431 Cr against equity of ₹5,682 Cr — a debt-to-equity of 0.08. Operating profit covers the interest bill 15×. Over 5 years borrowings went from ₹577 Cr to ₹431 Cr while capital spending ran ₹1,032 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 16% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 13.9 points of Cyient Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 14.5% of the company. Domestic institutions moved +7.8 points over the same window, to 37.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −13.9 points over 8 quarters to 14.5%; Domestic institutions: +7.8 points over 8 quarters to 37.5%; Promoters: +1.6 points over 8 quarters to 24.7%.
Why the register moved: rotation — foreign institutions −13.9 points against domestic institutions +7.8 points over 8 quarters, with promoters +1.6 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Cyient Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Persistent Systems LtdPERSISTENT | 76.7/100Favorable setup100% evidence | BREAKING OUT | 26.0/35 Revenue 25.4% · PAT 26.5% · OPM change -2 pp 100% evidence | 21.6/25 ROCE 34.4% · OPM 16% 100% evidence | 11.2/20 P/E 43.7× · PEG 1.07 100% evidence | 17.9/20 RS sector 8.8% · RS bench 2.1% · 1Y 7.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 26 + 21.6 + 11.2 + 17.9 = 76.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Onward Technologies LtdONWARDTEC | 60.6/100Mixed-positive evidence74% evidence | BREAKING OUT | 24.5/35 Revenue 10.7% · PAT 30.3% · OPM change -1 pp 95% evidence | 13.4/25 ROCE 22.9% · OPM 12% 95% evidence | 11.5/20 P/E 14× · PEG — 15% evidence | 11.2/20 RS sector 0.6% · RS bench 2.5% · 1Y -14.5%7 of 10 weeks ahead 70% evidence |
| Exact sum: 24.5 + 13.4 + 11.5 + 11.2 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3L&T Technology Services LtdLTTS | 56.6/100Mixed-positive evidence94% evidence | TURNING | 20.9/35 Revenue 10.1% · PAT 4.4% · OPM change 2 pp 100% evidence | 16.2/25 ROCE 26.7% · OPM 19% 100% evidence | 9.2/20 P/E 26.3× · PEG 3.84 100% evidence | 10.3/20 RS sector 2.4% · RS bench -9.7% · 1Y -19%1 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 16.2 + 9.2 + 10.3 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Tata Technologies LtdTATATECH | 46.2/100Mixed-negative evidence94% evidence | FADING | 14.1/35 Revenue 15.2% · PAT -18.5% · OPM change 0 pp 100% evidence | 11.1/25 ROCE 20.9% · OPM 16% 100% evidence | 5.0/20 P/E 47.6× · PEG 4.06 100% evidence | 16.0/20 RS sector 6.7% · RS bench 14.1% · 1Y 13.4%9 of 11 weeks ahead 70% evidence |
| Exact sum: 14.1 + 11.1 + 5 + 16 = 46.2 · Decision use: Price leads the evidence: RS versus the benchmark is 14.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5Tata Elxsi LtdTATAELXSI | 39.0/100Mixed-negative evidence100% evidence | ASLEEP | 12.3/35 Revenue 5.2% · PAT -12% · OPM change 0 pp 100% evidence | 18.1/25 ROCE 30% · OPM 21% 100% evidence | 7.1/20 P/E 29.9× · PEG 5.23 100% evidence | 1.5/20 RS sector -20.2% · RS bench -25.4% · 1Y -37.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 18.1 + 7.1 + 1.5 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Cyient Ltdthis pageCYIENT | 34.3/100Adverse evidence76% evidence | TURNING | 9.8/35 Revenue 3.2% · PAT -36.9% · OPM change 0 pp 95% evidence | 7.9/25 ROCE 12.3% · OPM 13% 76% evidence | 7.2/20 P/E 28.9× · PEG — 50% evidence | 9.4/20 RS sector -9.7% · RS bench 7.3% · 1Y -9.1%3 of 10 weeks ahead 70% evidence |
| Exact sum: 9.8 + 7.9 + 7.2 + 9.4 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7KPIT Technologies LtdKPITTECH | 33.3/100Adverse evidence94% evidence | ASLEEP | 6.2/35 Revenue 9.6% · PAT -28.1% · OPM change -4 pp 100% evidence | 14.9/25 ROCE 26.3% · OPM 15% 100% evidence | 9.2/20 P/E 24.3× · PEG 6.64 100% evidence | 3.0/20 RS sector -23.3% · RS bench -36.2% · 1Y -55.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 6.2 + 14.9 + 9.2 + 3 = 33.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Cyient Ltd's share price today?
Cyient Ltd trades at ₹1,059, −13.7% over the past year. The company is valued at ₹11,776 Cr. The stock sits at 66% of its 52-week range of ₹785–₹1,201, +7.2% versus its 200-day average. On the tape, the price is in a downtrend, 85 weeks in. — as of 11 September 2026.
What were Cyient Ltd's latest quarterly results?
Cyient Ltd reported revenue of ₹2,076 Cr and net profit of ₹109 Cr for the Jun 26 quarter. Revenue rose 21.3% and profit fell 30.6% year on year. Earnings per share were ₹9.37. The operating margin was 13.0%, 0.0 pp higher than a year earlier. — as of 11 September 2026.
What is Cyient Ltd's revenue?
Cyient Ltd reported revenue of ₹2,076 Cr in the Jun 26 quarter, +21.3% year on year. For the full FY26 fiscal year, revenue was ₹7,268 Cr (−1.2%). Over the last 10 years revenue compounded at 8.9% a year. — as of 11 September 2026.
What is Cyient Ltd's profit?
Cyient Ltd earned ₹109 Cr of net profit in the Jun 26 quarter, −30.6% year on year. Full-year FY26 profit was ₹463 Cr. The operating margin ran 13.0% in the latest quarter. — as of 11 September 2026.
What is Cyient Ltd's market cap?
Cyient Ltd's market capitalisation is ₹11,776 Cr at a share price of ₹1,059. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Cyient Ltd's P/E ratio?
Cyient Ltd trades at a P/E of 28.9×, at the 89th percentile of its own 11-year range, against a long-run median of 19.0×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Cyient Ltd pay a dividend?
Yes — Cyient Ltd's dividend payout was 42% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Cyient Ltd overvalued?
On its own history, Cyient Ltd looks expensive: its P/E of 28.9× sits at the 89th percentile of its 11-year range (long-run median 19.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Cyient Ltd growing?
Yes — Cyient Ltd is growing: latest-quarter revenue +21.3% year on year, profit −30.6%, and the margin +0.0 pp at 13.0%. The 10-year compound rates are 8.9% (revenue) and 3.8% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Cyient Ltd performing?
Cyient Ltd is in a downtrend, 85 weeks in. Its latest quarter's revenue rose 21.3% and profit fell 30.6% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Cyient Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −36.9% latest against +1.9% at its 12-quarter best), ROCE slipping at 12.0%. The read comes from the last 12 quarters of growth (revenue growth +3.2% latest, profit growth −36.9% latest, eps growth −39.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Cyient Ltd in an uptrend?
No — the price is in a downtrend (week 85 of stage 4), trading +7.2% versus its 200-day average and at 66% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Cyient Ltd beating the market?
On recent form, yes — Cyient Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +162% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will Cyient Ltd's share price go up?
This page publishes no price forecast for Cyient Ltd. What it measures instead: the share price is ₹1,059, the price is in a downtrend 85 weeks in. Its P/E of 28.9× sits at the 89th percentile of its own 11-year range. Direction is not something this site claims to know. — as of 11 September 2026.
Who owns Cyient Ltd?
Promoters hold 24.7% of Cyient Ltd, foreign institutions 14.5%, domestic institutions 37.5% and the public 22.7% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 13.9 points over 8 quarters. — as of 11 September 2026.
Does Cyient Ltd have too much debt?
No — Cyient Ltd's debt-to-equity is 0.08, and operating profit covers the interest bill 15×. FY26 borrowings were ₹431 Cr against equity of ₹5,682 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Cyient Ltd's capex?
Cyient Ltd spent ₹1,032 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹359 Cr, with ₹5.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Cyient Ltd's cash flow?
Cyient Ltd generated ₹787 Cr of operating cash flow in FY26 and ₹428 Cr of free cash flow after ₹359 Cr of capital spending. Reported profit that year was ₹463 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Cyient Ltd's profit real cash?
Yes — over the last 3 fiscal years, 127% of Cyient Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹787 Cr against reported profit of ₹463 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Cyient Ltd in its business cycle?
Cyient Ltd's FY26 operating margin was 12.0%, against a 13-year band of 12.0%–19.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 13.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Cyient Ltd's price assume?
At its price on 13 June 2026, Cyient Ltd was priced for profit growth of about 12.8% a year. Profit itself has compounded 3.8% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Cyient Ltd story?
The sharpest disagreement: the engine is strong, but at the 89th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Cyient Ltd a stock worth studying right now?
This is not investment advice. The machine read: Cyient Ltd is strength at full price. The numbers are improving — and a P/E at the 89th percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!